Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, continuous, hormone therapy, intermittent, outcome, survival | 5 Comments »
A new article offers expert perspective on the relative merits of intermittent and continuous androgen deprivation therapy (ADT) in the treatment of men with metastatic prostate cancer or recurrence of disease following first- or second-line treatment. … READ MORE …
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation, continuous, IADT, intermittent | 1 Comment »
Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen deprivation therapy, doubling time, IADT, intermittent, PSA, PSADT | 1 Comment »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
It has been suspected for many years that intermittent androgen deprivation (ADT) might have the same or a better impact on survival of prostate cancer patients as continuous ADT, with potentially superior effects on other factors such as quality of life. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, continuous, intermittent, randomized | 2 Comments »
A new report has suggested that, for men treated with intermittent androgen deprivation therapy (ADT) after biochemical relapse following surgery or radiation, the length of the first time-period off androgen deprivation therapy (ADT) may correlate with time to onset of castration-resistant prostate cancer (CRPC) and prostate cancer-specific mortality. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, castrration-resistant, CRPC, intermittent, survival | 1 Comment »
Today’s news reports cover items on:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 